AU2017382850B2 - Antibodies that specifically bind to human IL-15 and uses thereof - Google Patents

Antibodies that specifically bind to human IL-15 and uses thereof Download PDF

Info

Publication number
AU2017382850B2
AU2017382850B2 AU2017382850A AU2017382850A AU2017382850B2 AU 2017382850 B2 AU2017382850 B2 AU 2017382850B2 AU 2017382850 A AU2017382850 A AU 2017382850A AU 2017382850 A AU2017382850 A AU 2017382850A AU 2017382850 B2 AU2017382850 B2 AU 2017382850B2
Authority
AU
Australia
Prior art keywords
antibody
binding
ser
seq
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017382850A
Other languages
English (en)
Other versions
AU2017382850A1 (en
Inventor
Adam William Clarke
Anthony Gerard Doyle
David Jose Simon LAINE
Matthew Pollard
Lynn Dorothy Poulton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of AU2017382850A1 publication Critical patent/AU2017382850A1/en
Assigned to CEPHALON LLC reassignment CEPHALON LLC Amend patent request/document other than specification (104) Assignors: CEPHALON, INC.
Application granted granted Critical
Publication of AU2017382850B2 publication Critical patent/AU2017382850B2/en
Priority to AU2025201185A priority Critical patent/AU2025201185A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5443—IL-15

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
AU2017382850A 2016-12-21 2017-12-21 Antibodies that specifically bind to human IL-15 and uses thereof Active AU2017382850B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025201185A AU2025201185A1 (en) 2016-12-21 2025-02-20 Antibodies that specifically bind to human IL-15 and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437143P 2016-12-21 2016-12-21
US62/437,143 2016-12-21
PCT/US2017/067917 WO2018119246A1 (en) 2016-12-21 2017-12-21 Antibodies that specifically bind to human il-15 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025201185A Division AU2025201185A1 (en) 2016-12-21 2025-02-20 Antibodies that specifically bind to human IL-15 and uses thereof

Publications (2)

Publication Number Publication Date
AU2017382850A1 AU2017382850A1 (en) 2019-07-04
AU2017382850B2 true AU2017382850B2 (en) 2024-11-21

Family

ID=62627610

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017382850A Active AU2017382850B2 (en) 2016-12-21 2017-12-21 Antibodies that specifically bind to human IL-15 and uses thereof
AU2025201185A Abandoned AU2025201185A1 (en) 2016-12-21 2025-02-20 Antibodies that specifically bind to human IL-15 and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025201185A Abandoned AU2025201185A1 (en) 2016-12-21 2025-02-20 Antibodies that specifically bind to human IL-15 and uses thereof

Country Status (30)

Country Link
US (2) US11267883B2 (enExample)
EP (2) EP3558369B1 (enExample)
JP (2) JP7155126B2 (enExample)
KR (2) KR20190097094A (enExample)
CN (1) CN110234349B (enExample)
AR (1) AR110414A1 (enExample)
AU (2) AU2017382850B2 (enExample)
BR (1) BR112019012570A8 (enExample)
CA (1) CA3046387A1 (enExample)
CL (1) CL2019001729A1 (enExample)
DK (1) DK3558369T3 (enExample)
EA (1) EA201991514A1 (enExample)
ES (1) ES3026508T3 (enExample)
FI (1) FI3558369T3 (enExample)
HR (1) HRP20250482T1 (enExample)
HU (1) HUE071878T2 (enExample)
IL (1) IL267113B2 (enExample)
LT (1) LT3558369T (enExample)
MA (1) MA47130B1 (enExample)
MD (1) MD3558369T2 (enExample)
MX (2) MX2019007357A (enExample)
PE (1) PE20191497A1 (enExample)
PH (1) PH12019501453A1 (enExample)
PL (1) PL3558369T3 (enExample)
PT (1) PT3558369T (enExample)
RS (1) RS66900B1 (enExample)
SI (1) SI3558369T1 (enExample)
UA (1) UA126284C2 (enExample)
WO (1) WO2018119246A1 (enExample)
ZA (1) ZA201903848B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI695067B (zh) 2013-08-05 2020-06-01 美商扭轉生物科技有限公司 重新合成之基因庫
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
WO2016172377A1 (en) 2015-04-21 2016-10-27 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
CN108368482A (zh) 2015-09-18 2018-08-03 特韦斯特生物科学公司 寡核酸变体文库及其合成
US11512347B2 (en) 2015-09-22 2022-11-29 Twist Bioscience Corporation Flexible substrates for nucleic acid synthesis
EP3516528B1 (en) 2016-09-21 2025-10-15 Atlas Data Storage, Inc. Nucleic acid based data storage
MA47130B1 (fr) 2016-12-21 2025-05-30 Cephalon, Inc. Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations
JP2020508661A (ja) 2017-02-22 2020-03-26 ツイスト バイオサイエンス コーポレーション 核酸ベースのデータ保存
WO2018231872A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
US11407837B2 (en) 2017-09-11 2022-08-09 Twist Bioscience Corporation GPCR binding proteins and synthesis thereof
CA3079613A1 (en) 2017-10-20 2019-04-25 Twist Bioscience Corporation Heated nanowells for polynucleotide synthesis
KR20250069684A (ko) 2018-01-04 2025-05-19 트위스트 바이오사이언스 코포레이션 Dna 기반 디지털 정보 저장
CN118957038A (zh) 2018-05-18 2024-11-15 特韦斯特生物科学公司 用于核酸杂交的多核苷酸、试剂和方法
EP3827079A1 (en) 2018-07-25 2021-06-02 Askgene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
US11828385B2 (en) 2018-12-25 2023-11-28 Ntn Corporation Flow control valve seal and flow control valve device
WO2020139871A1 (en) 2018-12-26 2020-07-02 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
JP2022521551A (ja) 2019-02-26 2022-04-08 ツイスト バイオサイエンス コーポレーション Ｇｌｐ１受容体の変異体核酸ライブラリ
US11492728B2 (en) 2019-02-26 2022-11-08 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
WO2020257612A1 (en) 2019-06-21 2020-12-24 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
CN115003697A (zh) 2019-09-23 2022-09-02 特韦斯特生物科学公司 Crth2的变异核酸文库
US12173282B2 (en) 2019-09-23 2024-12-24 Twist Bioscience, Inc. Antibodies that bind CD3 epsilon
CN115066518A (zh) * 2019-12-09 2022-09-16 特韦斯特生物科学公司 针对腺苷受体的变体核酸文库
EP4229093A1 (en) * 2020-10-16 2023-08-23 Genentech, Inc. Anti-cleaved icaspase substrate antibodies and methods of use
JP2024504384A (ja) 2021-01-21 2024-01-31 ツイスト バイオサイエンス コーポレーション アデノシン受容体に関する方法および組成物
CN113185600A (zh) * 2021-05-28 2021-07-30 苏州复融生物技术有限公司 一种新型白介素15突变体多肽的开发及其应用
KR20250044344A (ko) 2022-08-04 2025-03-31 노파르티스 파르마 아게 아토피 피부염의 치료에 유용한 il-15 저해제
CN118894934A (zh) * 2023-05-05 2024-11-05 北京智仁美博生物科技有限公司 抗人il-15的抗体及其用途
CN117209605B (zh) * 2023-11-09 2024-01-30 北京百普赛斯生物科技股份有限公司 特异性结合il-15的抗体及其应用
WO2025227052A1 (en) 2024-04-26 2025-10-30 Cephalon Llc Doses and formulations of anti-il-15 antibody for the treatment of immune diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165466A (en) * 1995-02-22 2000-12-26 Immunex Corporation Antagonists of interleukin-15
US7329405B2 (en) * 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
EP2963057A1 (en) * 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7132510B2 (en) 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
PT1425389E (pt) * 2001-08-23 2012-02-07 Genmab As Anticorpos humanos específicos para interleucina 15 (il-15)
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2508375C (en) * 2002-12-02 2014-05-27 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
EA015897B1 (ru) * 2003-02-26 2011-12-30 Генмаб А/С Применение человеческого моноклонального антитела к ил-15 в составе композиции и лекарственного препарата (варианты), композиция и лекарственный препарат, его включающие
WO2006017853A2 (en) * 2004-08-11 2006-02-16 Beth Israel Deaconess Medical Center, Inc. Mutant interleukin-15-containing compositions and suppression of an immune response
WO2006090750A1 (ja) 2005-02-28 2006-08-31 Institute For Antibodies Co., Ltd. 抗IgSF4抗体及びその利用
PL2161336T5 (pl) * 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
SI2602323T1 (en) 2007-06-01 2018-05-31 Open Monoclonal Technology, Inc. Compositions and procedures for inhibiting endogenous immunoglobin gene and the formation of transgenic human idiopathic antibodies
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
DK2792236T4 (da) 2009-07-08 2023-05-15 Kymab Ltd Dyremodeller og terapeutiske molekyler
MX2012004412A (es) * 2009-10-15 2012-05-08 Abbott Lab Proteinas de union a il-1.
EP4012714A1 (en) * 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
NZ604415A (en) 2010-07-20 2014-10-31 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
JP5820688B2 (ja) 2011-03-23 2015-11-24 株式会社Kri 多糖類の溶解に用いられる溶媒ならびに該溶媒を用いた成形体および多糖類誘導体の製造方法
RU2014109038A (ru) * 2011-08-23 2015-09-27 Рош Гликарт Аг Антитела к хондроитинсульфат протеогликану меланомы
BR112014009925B1 (pt) * 2011-10-28 2022-09-20 Teva Pharmaceuticals Australia Pty Ltd Construtores de polipeptídeos e seus usos
EP2961773B1 (en) 2013-02-26 2019-03-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
JP6862351B2 (ja) 2015-03-31 2021-04-21 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法
MX2018015363A (es) * 2016-06-15 2019-04-15 Amgen Inc Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria.
UA128669C2 (uk) 2016-10-14 2024-09-25 Ксенкор, Інк. ГЕТЕРОДИМЕРНИЙ Fc-ЗЛИТИЙ БІЛОК IL15/IL15Ra
MA47130B1 (fr) 2016-12-21 2025-05-30 Cephalon, Inc. Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165466A (en) * 1995-02-22 2000-12-26 Immunex Corporation Antagonists of interleukin-15
US7329405B2 (en) * 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
EP2963057A1 (en) * 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERNARD J, et al., 'Identification of an interleukin-15alpha receptor-binding site on human interleukin-15', Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, (2004), vol 279 no. 23, pp 24313-24322. *
GORSKI K, et al., 1 April 2016, XP055342756, FOI 10.1016/S0016-5085(16) 30690-4, Retrieved from the Internet: URL:http://www.gastrojournal.org/article/S0016-5085(16)30690-4/pdf. [retrieved on 20217-02-20]. *

Also Published As

Publication number Publication date
PL3558369T3 (pl) 2025-06-23
JP2022176324A (ja) 2022-11-25
MX2019007357A (es) 2019-09-05
PE20191497A1 (es) 2019-10-21
ZA201903848B (en) 2023-02-22
JP7155126B2 (ja) 2022-10-18
EA201991514A1 (ru) 2019-12-30
EP4585261A2 (en) 2025-07-16
MD3558369T2 (ro) 2025-08-31
LT3558369T (lt) 2025-07-25
FI3558369T3 (fi) 2025-05-02
KR20190097094A (ko) 2019-08-20
ES3026508T3 (en) 2025-06-11
EP4585261A3 (en) 2025-08-13
CA3046387A1 (en) 2018-06-28
US20200270339A1 (en) 2020-08-27
HRP20250482T1 (hr) 2025-06-20
DK3558369T3 (da) 2025-05-19
PT3558369T (pt) 2025-05-06
JP2020501583A (ja) 2020-01-23
CN110234349B (zh) 2024-03-22
AR110414A1 (es) 2019-03-27
IL267113A (en) 2019-08-29
RS66900B1 (sr) 2025-07-31
MA47130A (fr) 2019-10-30
IL267113B2 (en) 2024-09-01
AU2025201185A1 (en) 2025-03-13
US12410247B2 (en) 2025-09-09
US11267883B2 (en) 2022-03-08
IL267113B1 (en) 2024-05-01
KR102706743B1 (ko) 2024-09-19
WO2018119246A1 (en) 2018-06-28
UA126284C2 (uk) 2022-09-14
MA47130B1 (fr) 2025-05-30
BR112019012570A2 (pt) 2019-11-26
KR20230135691A (ko) 2023-09-25
PH12019501453A1 (en) 2020-06-15
SI3558369T1 (sl) 2025-06-30
MX2023014081A (es) 2023-12-06
AU2017382850A1 (en) 2019-07-04
CL2019001729A1 (es) 2019-09-13
US20220127352A1 (en) 2022-04-28
BR112019012570A8 (pt) 2023-01-24
HUE071878T2 (hu) 2025-09-28
EP3558369B1 (en) 2025-03-26
EP3558369A1 (en) 2019-10-30
CN110234349A (zh) 2019-09-13
EP3558369A4 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
AU2017382850B2 (en) Antibodies that specifically bind to human IL-15 and uses thereof
AU2016364889B2 (en) Antibodies and methods of use thereof
AU2021285330B2 (en) SARS-CoV-2 spike protein binding molecule and application thereof
AU2019302152B2 (en) Anti-sirpalpha antibody
AU2018338859B2 (en) Multispecific antigen-binding molecule having blood coagulation factor VIII (FVIII) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
AU2017233658B2 (en) Cell injury inducing therapeutic drug for use in cancer therapy
AU2018247797B2 (en) Anti-LAG3 antibodies
AU2017296095B2 (en) Multispecific antibodies against CD40 and CD137
AU2017256786B2 (en) Binding molecules specific for FcγGamma RIIA and uses thereof
AU2016326449B2 (en) CD3 binding polypeptides
AU2016372934B2 (en) Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
CN108137686B (zh) 抗ox40抗体及其使用方法
AU2017373945B2 (en) Antibodies and methods of use thereof
AU2020226904B2 (en) Anti-TCR antibody molecules and uses thereof
AU2021255445B2 (en) Antibody to human interleukin-4 receptor α, preparation method therefor and use thereof
AU2017231833B2 (en) ILT7 binding molecules and methods of using the same
AU2016361462B2 (en) CD131 binding proteins and uses thereof
AU2021301921B2 (en) Bispecific antibody and use thereof
AU2018213374B2 (en) Glucagon receptor binding proteins and methods of use thereof
AU2022219332A1 (en) Anti-cd112r antibody and use thereof
AU2022269145A1 (en) Fc mutant with altered binding to fc receptor
AU2020381735B2 (en) Molecule capable of binding to human 4-1BB, and application of molecule
HK40013673A (en) Antibodies that specifically bind to human il-15 and uses thereof
HK40013673B (en) Antibodies that specifically bind to human il-15 and uses thereof
AU2021362977A9 (en) Anti-trop-2 antibody, antigen-binding fragment thereof or mutant thereof, and medical use thereof

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: CEPHALON LLC

Free format text: FORMER NAME(S): CEPHALON, INC.

FGA Letters patent sealed or granted (standard patent)